SEC Form 4 · accession 0001437749-26-022154
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Krempa
Officer — Chief Business Officer
Period of report
Jun 26, 2026
Accepted (ET)
Jun 30, 2026 · 4:27 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710340
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jun 26, 2026 | A | 10,000 | A | — | — | Common Stock | 10,000 | 96,829 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
- F2The restricted stock units vest in four equal annual installments beginning June 26, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.